Bristol reviews Plavix ad
Bristol-Myers Squibb has conducted an audit of a recent Plavix direct-to-consumer ad and maintains that there is no difference in the speed of delivery between efficacy and safety/risk information in voiceovers. At a recent Regulatory Affairs Professional Society DTC conference, a Bristol regulatory director agreed with attendees that the voice delivering the safety information was faster (1"The Pink Sheet" May 22, 2006, p. 27). Attendees also said the change from a male voice to a female voice for delivery of the safety/risk information was distracting. Bristol said it intentionally switched voices to call attention to safety/risk information and noted that the ad was pre-cleared by FDA...
You may also be interested in...
As industry continues to implement PhRMA's guidelines on direct-to-consumer ads, debate has arisen as to how companies can effectively enact the principle that advertising should encourage a conversation between patient and physician
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
The recently US FDA-cleared Velys robotic-assisted system from DePuy Synthes has distinct features. It also has a small footprint that makes it well-suited for ambulatory surgery centers. See what Larry Biegelsen, an analyst with Wells Fargo, said about it here.